Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lipella PharmaceuticalsLIPO EV-to-OCF is 0.33 as of Aug. 10, 2026. The stock has 1 warning sign investors should review. Among 1,407 Biotechnology companies, Lipella Pharmaceuticals ranks worse than 74.77% on this metric.
The historical rank and industry rank for Lipella Pharmaceuticals's EV-to-OCF or its related term are showing as below:
LIPO'
s EV-to-OCF Range Over the Past 10 Years
Min: -11.19 Med: -0.56 Max: 0.59
Current: 0.33
During the past 5 years, the highest EV-to-OCF of Lipella Pharmaceuticals was 0.59. The lowest was -11.19. And the median was -0.56.
LIPO's EV-to-OCF is ranked worse than 74.77% of 1407
companies
in the Biotechnology industry
Industry Median: -3.45
vs LIPO: 0.33
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lipella Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Lipella Pharmaceuticals's share price for today is $0.0002.
Lipella Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.420.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lipella Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipella Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Lipella Pharmaceuticals's EV-to-OCF falls into.
Lipella Pharmaceuticals's current Enterprise Value is $-1.59 Mil.
Lipella Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipella Pharmaceuticals (LIPO) has a EV-to-OCF of 0.33 as of Aug. 10, 2026. According to the industry distribution chart, Lipella Pharmaceuticals ranks #1052 out of 1407 companies in the Biotechnology industry, placing it in the top 74.8%.
Is Lipella Pharmaceuticals' EV-to-OCF too high?
Lipella Pharmaceuticals' current EV-to-OCF is 0.33. Based on the distribution chart, Lipella Pharmaceuticals ranks #1052 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint.
How does Lipella Pharmaceuticals' EV-to-OCF compare to SIGY and CNBX?
According to the Biotechnology industry distribution chart, Lipella Pharmaceuticals ranks #1052 out of 1407 companies for EV-to-OCF. This places Lipella Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Lipella Pharmaceuticals's current EV-to-OCF is 0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.79, compared to a current price of $0.00 — trading 100% below its estimated fair value. The current EV-to-OCF is 0.33. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current EV-to-OCF is 0.33 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIPO has been successfully added to your 
